What are the preferred regimens for second-line and subsequent therapy in the treatment of B-cell follicular lymphoma?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Preferred regimens for second-line and subsequent therapy are as follows:

  • Bendamustine + obinutuzumab or rituximab
  • CHOP + obinutuzumab or rituximab
  • CVP + obinutuzumab or rituximab
  • Rituximab
  • Lenalidomide ± rituximab
  • Ibritumomab tiuxetan
  • Lenalisomide if patient is not a candidate for anti-CD20 monoclonal antibody therapy
  • Lenalidomide + obinutuzumab
  • Obinutuzumab
  • PI3K inhibitors for relapsed or refractory after 2 prior therapies
    • Copanlisib
    • Duvelisib
    • Idelalisib
  • Umbralisib- Dual inhibitor of PI3K and casein kinase epsilon

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!